

Putting NICE guidance into practice

Costing statement: Implementing the NICE guidance on lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality (TA322)

Published: September 2014

The commissioner for this technology is NHS England.

The company (Celgene) has agreed a standard patient access scheme with the Department of Health, in which the NHS pays for lenalidomide treatment for up to 26 monthly cycles. The company subsequently provides free of charge lenalidomide for those people who receive more than 26 monthly cycles.

The number of new people eligible for treatment with lenalidomide is around 200 per year for the population of England. The cost impact for treating these people is estimated to be approximately £5.6 million for year 1 and £3 million for year 2. When the patient access scheme comes into effect, after 26 cycles, a cost saving of around £70,000 is expected.

Any queries from NHS organisations about the patient access scheme should be directed to Celgene Europe Limited (sdhanasiri@celgene.com).